Search results for: Sweden
Filter search results
Value Based Pricing in Sweden: Lessons for Design?
28 November 2012
…which is the health technology assessment (HTA) agency in Sweden. In Sweden, the TLV makes decisions on the reimbursement status of new medicines, under a system introduced in 2002. Its…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight to cost-offsets outside the…
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…availability of certain antibiotics in Sweden, with Sweden gaining access to some new medicines earlier than comparable countries. The model was simple, transparent, and reasonably flexible. However, the pilot highlighted…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…Institute for Health Economics (IHE) in Sweden shows that health systems and societies in general (consumers) were able to appropriate most of the life-cycle value (surplus) generated by SGAs in…
Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds
31 March 2026
…the world each year, roughly equivalent to the GDP of Sweden. ASCVD, a condition characterised by plaque build-up in the arteries, is the leading cause of cardiovascular illness and death. Its global…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
…of cancer medicines in Sweden is close to or above the international level. In 2012/13 Sweden’s overall ranking across all of the medicines studied for usage per person remains 12th…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…devices. American Economic Review, 103(1), 145-77. Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A (2019). The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
…Italy, Sweden, the Netherlands, the UK and the US1. Two years later, Lilly commissioned a second report based on the South Korean setting, following the same method and structure as…